Loading the list…

ImmunityBio, Inc. (IBRX)

Nasdaq · IBRX

connecting

$6.03−0.74%

Closing prices for 13 November 2026

Loading chart

Company valuation

The series is stated in the current share scale after splits; dividends are not included in the price

Volatility 90d

79.26%

Place in range

38.88%

ImmunityBio, Inc. (IBRX) is a public company in the healthcare sector. Its common stock trade on NASDAQ.

This summary is compiled automatically from SEC filings and exchange data.

Operating margin

−151.88%sector median −20.96%

Current ratio

5.7

Revenue, last year

$166M

Net income, last year

−$992M

Earnings per share

−$0.95

Revenue growth, year over year

+192.92%sector median 7.81%

Based on the last 12 months of reports, through 30 June 2026

The sector median covers every company in the sector on the US market, loss-making ones included.

How to read the figures

Market capitalisation is the value of all of a company's shares at the current price: the price of one share times the number of shares.
P/S (price / sales) is market capitalisation divided by revenue over 12 months: what the market pays for each unit of sales. Useful when there is no profit yet.
ROA (return on assets) is net income divided by total assets: how efficiently the company uses what it owns.
Net margin is the share of net income in revenue: how much profit remains from each unit of sales.
Operating margin is the share of profit from core operations in revenue, before interest and taxes.
The current ratio is current assets divided by short-term liabilities: whether the company has enough cash and inventory to pay its nearest debts.
Revenue growth is the change in revenue over the last 12 months against the same period a year earlier.